Home › Companies › GENERATION BIO CO. › 2023-2024

GENERATION BIO CO. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and GENERATION BIO CO.’s Form 8-K, filed 2024-06-07 (Item 5.07 on EDGAR). Page generated 02 October 2026.

5Ballot items
109Asset managers
730Fund votes
2024-06-06Meeting date

Proxy season: 2023-2024

Explore GENERATION BIO CO. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by GENERATION BIO CO.

These tallies are GENERATION BIO CO.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-07 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

GENERATION BIO CO. — official shareholder meeting results, meeting held 2024-06-06
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Jeffrey Jonas, M.D.	35,807,200	--	--	12,353,347	5,410,328	Majority: yes
Elect Director: Geoff McDonough, M.D.	47,658,822	--	--	501,725	5,410,328	Majority: yes
Elect Director: Donald Nicholson, Ph.D.	47,589,073	--	--	571,474	5,410,328	Majority: yes
Proposal 2: . Ratification of Appointment of Ernst & Young LLP.	53,562,165	1,795	6,915	--	--	Majority: yes
Proposal 3: . Advisory (Non-Binding) Vote on Executive Compensation	47,772,176	373,246	15,125	--	5,410,328	Majority: yes

Source: GENERATION BIO CO., Form 8-K, filed with the SEC on 2024-06-07 — read the filing on EDGAR.

How asset managers voted at the GENERATION BIO CO. 2023-2024 meeting

Each item below shows how the 109 asset managers that disclosed a GENERATION BIO CO. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Approval, on an advisory (non- binding) basis, of the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%

FOR: 47,772,176AGAINST: 373,246

GENERATION BIO CO.’s own tally for this item (“Proposal 3: . Advisory (Non-Binding) Vote on Executive Compensation”): 47,772,176 for, 373,246 against, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 66,528,840 outstanding shares: 72% for, 0.6% against (72% of the company cast a for/against vote).

The 109 asset managers below cast 99% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 99%

FOR: 98.9%AGAINST: 1.1%

Largest asset managers voting on “Approval, on an advisory (non- binding) basis, of the compensation of our named executive officers.” at GENERATION BIO CO., 2023-2024
Asset manager	For	Against	Vote
T. Rowe Price	17,030,641	0	For
Fidelity	9,715,290	0	For
Atlas Venture Life Science Advisors, LLC	8,278,876	0	For
Vanguard	2,576,396	0	For
BlackRock	2,268,387	593	For
EcoR1 Capital, LLC	2,046,867	0	For
PFM Health Sciences, LP	1,622,487	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,069,389	0	For
Goldman Sachs	1,058,373	0	For
State Street	934,436	46	For
Charles Schwab	778,902	0	For
Dimensional	441,934	0	For
SEI	431,124	0	For
Renaissance	245,486	0	For
BRIDGEWAY CAPITAL MANAGEMENT, LLC	0	241,600	Against
BRIDGEWAY FUNDS INC	0	241,600	Against
Northern Trust	228,461	0	For
DE Shaw	228,248	0	For
ACADIAN ASSET MANAGEMENT LLC	196,715	0	For
JPMorgan	196,499	0	For
Two Sigma	194,837	0	For
Equitable	178,978	0	For
MELLON INVESTMENTS Corp	175,974	0	For
Nuveen	150,965	0	For
Yiheng Capital Management, L.P.	149,976	0	For

Showing the 25 largest of 109 asset managers. See all 109 in the interactive database.

2. Election of three Class I directors to our board of directors, each to serve until the 2027 Annual Meeting of Stockholders: Geoff McDonough

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 47,658,822WITHHELD: 501,725

GENERATION BIO CO.’s own tally for this item (“Elect Director: Geoff McDonough, M.D.”): 47,658,822 for, 501,725 withheld, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 66,528,840 outstanding shares: 72% for, 0.8% withheld (72% of the company cast a for/withheld vote).

The 38 asset managers below cast 100% of the shares they voted on this item FOR (17,504,814 for, 0 against).

FOR 98%

FOR: 17,504,814 (98.1%)ABSTAIN: 337,972 (1.9%)

Largest asset managers voting on “Election of three Class I directors to our board of directors, each to serve until the 2027 Annual Meeting of ” at GENERATION BIO CO., 2023-2024
Asset manager	For	Abstain	Vote
T. Rowe Price	7,594,583	0	For
Fidelity	4,384,109	0	For
Vanguard	2,533,447	0	For
BlackRock	1,143,240	0	For
Charles Schwab	389,451	0	For
Dimensional	0	318,340	Abstain
BRIDGEWAY FUNDS INC	241,600	0	For
Goldman Sachs	219,730	0	For
SEI	215,561	0	For
Equitable	178,978	0	For
TIAA	148,392	0	For
John Hancock	101,820	4,046	For
QUANTITATIVE MASTER SERIES LLC	79,184	0	For
Managed Portfolio Series	44,094	0	For
Lincoln Financial	39,000	2,510	For
AIG/SunAmerica	22,317	0	For
Northern Trust	21,499	0	For
Bridge Builder Trust	18,778	0	For
Pacific Life	18,619	0	For
Nationwide	17,332	0	For
State Street	16,681	0	For
Voya	16,253	0	For
TARGET PORTFOLIO TRUST	12,800	0	For
Jackson National	0	11,785	Abstain
American Century	10,895	0	For

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

3. Election of three Class I directors to our board of directors, each to serve until the 2027 Annual Meeting of Stockholders: Donald Nicholson

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 47,589,073WITHHELD: 571,474

GENERATION BIO CO.’s own tally for this item (“Elect Director: Donald Nicholson, Ph.D.”): 47,589,073 for, 571,474 withheld, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 66,528,840 outstanding shares: 72% for, 0.9% withheld (72% of the company cast a for/withheld vote).

The 38 asset managers below cast 100% of the shares they voted on this item FOR (17,436,619 for, 0 against).

FOR 98%

FOR: 17,436,619 (97.7%)ABSTAIN: 406,167 (2.3%)

Largest asset managers voting on “Election of three Class I directors to our board of directors, each to serve until the 2027 Annual Meeting of ” at GENERATION BIO CO., 2023-2024
Asset manager	For	Abstain	Vote
T. Rowe Price	7,594,583	0	For
Fidelity	4,384,109	0	For
Vanguard	2,533,447	0	For
BlackRock	1,143,240	0	For
Charles Schwab	389,451	0	For
Dimensional	0	318,340	Abstain
BRIDGEWAY FUNDS INC	241,600	0	For
Goldman Sachs	219,730	0	For
SEI	215,561	0	For
Equitable	110,783	68,195	For
TIAA	148,392	0	For
John Hancock	101,820	4,046	For
QUANTITATIVE MASTER SERIES LLC	79,184	0	For
Managed Portfolio Series	44,094	0	For
Lincoln Financial	39,000	2,510	For
AIG/SunAmerica	22,317	0	For
Northern Trust	21,499	0	For
Bridge Builder Trust	18,778	0	For
Pacific Life	18,619	0	For
Nationwide	17,332	0	For
State Street	16,681	0	For
Voya	16,253	0	For
TARGET PORTFOLIO TRUST	12,800	0	For
Jackson National	0	11,785	Abstain
American Century	10,895	0	For

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

4. Election of three Class I directors to our board of directors, each to serve until the 2027 Annual Meeting of Stockholders: Jeffrey Jonas

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD 26%

FOR: 35,807,200WITHHELD: 12,353,347

GENERATION BIO CO.’s own tally for this item (“Elect Director: Jeffrey Jonas, M.D.”): 35,807,200 for, 12,353,347 withheld, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 66,528,840 outstanding shares: 53.8% for, 19% withheld (72% of the company cast a for/withheld vote).

The 38 asset managers below cast 100% of the shares they voted on this item FOR (13,985,696 for, 0 against).

FOR 78%ABSTAIN 22%

FOR: 13,985,696 (78.4%)ABSTAIN: 3,857,090 (21.6%)

Largest asset managers voting on “Election of three Class I directors to our board of directors, each to serve until the 2027 Annual Meeting of ” at GENERATION BIO CO., 2023-2024
Asset manager	For	Abstain	Vote
T. Rowe Price	7,594,583	0	For
Fidelity	4,384,109	0	For
Vanguard	0	2,533,447	Abstain
BlackRock	1,143,240	0	For
Charles Schwab	389,451	0	For
Dimensional	0	318,340	Abstain
BRIDGEWAY FUNDS INC	0	241,600	Abstain
Goldman Sachs	0	219,730	Abstain
SEI	0	215,561	Abstain
Equitable	110,783	68,195	For
TIAA	148,392	0	For
John Hancock	83,285	22,581	For
QUANTITATIVE MASTER SERIES LLC	79,184	0	For
Managed Portfolio Series	0	44,094	Abstain
Lincoln Financial	0	41,510	Abstain
AIG/SunAmerica	0	22,317	Abstain
Northern Trust	0	21,499	Abstain
Bridge Builder Trust	18,778	0	For
Pacific Life	18,619	0	For
Nationwide	566	16,766	Abstain
State Street	0	16,681	Abstain
Voya	0	16,253	Abstain
TARGET PORTFOLIO TRUST	12,800	0	For
Jackson National	0	11,785	Abstain
American Century	0	10,895	Abstain

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

5. Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

AUDIT-RELATEDMajority of the votes cast: yes

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 53,562,165AGAINST: 1,795

GENERATION BIO CO.’s own tally for this item (“Proposal 2: . Ratification of Appointment of Ernst & Young LLP.”): 53,562,165 for, 1,795 against, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 66,528,840 outstanding shares: 81% for, 0.1% against (81% of the company cast a for/against vote).

The 38 asset managers below cast 100% of the shares they voted on this item FOR (17,842,786 for, 0 against).

FOR 100%

FOR: 17,842,786 (100.0%)

Largest asset managers voting on “Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for ” at GENERATION BIO CO., 2023-2024
Asset manager	For	Vote
T. Rowe Price	7,594,583	For
Fidelity	4,384,109	For
Vanguard	2,533,447	For
BlackRock	1,143,240	For
Charles Schwab	389,451	For
Dimensional	318,340	For
BRIDGEWAY FUNDS INC	241,600	For
Goldman Sachs	219,730	For
SEI	215,561	For
Equitable	178,978	For
TIAA	148,392	For
John Hancock	105,866	For
QUANTITATIVE MASTER SERIES LLC	79,184	For
Managed Portfolio Series	44,094	For
Lincoln Financial	41,510	For
AIG/SunAmerica	22,317	For
Northern Trust	21,499	For
Bridge Builder Trust	18,778	For
Pacific Life	18,619	For
Nationwide	17,332	For
State Street	16,681	For
Voya	16,253	For
TARGET PORTFOLIO TRUST	12,800	For
Jackson National	11,785	For
American Century	10,895	For

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

Largest GENERATION BIO CO. shareholders voting in 2023-2024

Ranked by the number of GENERATION BIO CO. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 66,528,840 shares outstanding at the time of that meeting.

Top GENERATION BIO CO. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	T. Rowe Price	25.60%
2	Fidelity	14.60%
3	Atlas Venture Life Science Advisors, LLC	12.44%
4	Vanguard	3.87%
5	BlackRock	3.41%
6	EcoR1 Capital, LLC	3.08%
7	PFM Health Sciences, LP	2.44%
8	GEODE CAPITAL MANAGEMENT, LLC	1.61%
9	Goldman Sachs	1.59%
10	State Street	1.40%

Reported GENERATION BIO CO. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

GENERATION BIO CO. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
T. Rowe Price	13.35%	13F
Jason Rhodes	12.61%	DEF14A
Entities affiliated with Atlas Venture Life Science Advisors	12.44%	DEF14A
Entities affiliated with T Rowe Price Associates	10.41%	DEF14A
ModernaTX	8.81%	DEF14A
Entities affiliated with Fidelity Investment	8.05%	DEF14A
Entities affiliated with BB Biotech AG	5.42%	DEF14A
BB Biotech AG	4.98%	13G
Geoff McDonough, M.D.	3.84%	DEF14A
Geode Capital	1.61%	13F

Percentages above are of 66,528,840 shares outstanding, as reported by GENERATION BIO CO. on its Form 10-Q dated 2024-05-08 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from GENERATION BIO CO.’s 10-Q dated 2024-05-08. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At GENERATION BIO CO.'s shareholder meeting held 2024-06-06, in the 2023-2024 proxy season, 109 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 730 separate fund positions. On the most widely held item on that ballot — Approval, on an advisory (non- binding) basis, of the compensation of our named executive… — FOR was 99.2% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: GENERATION BIO CO.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-07.

GENERATION BIO CO. proxy season coverage: 2023-2024 (this page).